Viking's VK2735 mimics both GLP-1 and GIP hormones, aiming for superior weight loss compared to established medications like Novo Nordisk A/S's (NYSE:NVO) Wegovy and Eli Lilly And Co's (NYSE:LLY) ...
Topping Viking's portfolio with a 5.6% allocation, U.S. Bancorp represents a significant long-term bet. Viking increased its position by 32.33% in Q3, bringing its total to 33.6 million shares worth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results